ETRA Electra Therapeutics, Inc.
Fundamentals / CIK 0002088082 / USDElectra Therapeutics, Inc. reported $410.8M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ETRA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$402.5M Total debt: $1.71M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Research & Development | $17.27M | -- | -- | $14.90M | -- | -- |
| Total Operating Expenses | $25.06M | -- | -- | $17.02M | -- | -- |
| Operating Income | -$25.06M | -- | -- | -$17.02M | -- | -- |
| Interest Income | $1.13M | -- | -- | $232K | -- | -- |
| Interest Expense | $0 | -- | -- | $1.30M | -- | -- |
| Net Income | -$23.93M | -$26.75M | -$22.17M | -$18.09M | -$17.57M | -$7.79M |
| Basic EPS | -$3.47 | -- | -- | -$616.86 | -- | -- |
| Diluted EPS | -$3.47 | -- | -- | -$616.86 | -- | -- |
| Basic Shares Outstanding | 6.9M | -- | -- | 29.3K | -- | -- |
| Diluted Shares Outstanding | 6.9M | -- | -- | 29.3K | -- | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2025-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $256.4M | $33.01M |
| Short-Term Investments | $146.1M | $53.51M |
| Cash & Short-Term Investments | $402.5M | $86.52M |
| Total Current Assets | $406.9M | $95.49M |
| Property, Plant & Equipment, Net | $518K | $674K |
| Other Non-Current Assets | $1.80M | $1.10M |
| Total Non-Current Assets | $3.89M | $3.88M |
| Total Assets | $410.8M | $99.37M |
| Accounts Payable | $8.06M | $4.08M |
| Total Current Liabilities | $16.98M | $9.73M |
| Long-Term Debt | $0 | -- |
| Total Non-Current Liabilities | $939K | $1.48M |
| Total Liabilities | $17.92M | $11.21M |
| Total Debt (incl. Leases) | $1.71M | $2.09M |
| Common Stock | $6.0K | $0 |
| Retained Earnings | -$245.8M | -$173.0M |
| Accumulated Other Comp. Income | $13K | $21K |
| Total Stockholders' Equity | $392.9M | -$163.4M |
| Total Equity | $392.9M | -$163.4M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$23.93M | -$26.75M | -$22.17M | -$18.09M | -$17.57M | -$7.79M |
| Stock-Based Compensation | $4.59M | -- | -- | $302K | -- | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 23.97x | -- | -- | -- | -- | -- |
| Quick Ratio | 23.71x | -- | -- | -- | -- | -- |
| Debt to Equity | 0.00x | -- | -- | -- | -- | -- |